JNJ

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed/refractory multiple myeloma in an earlier treatment line (second-line). The MonumenTAL-3 Phase III trial demonstrated significant improvements in progression-free survival (81% at 24 months) and overall survival (89% at 24 months) compared to the control arm, with safety profiles consistent with individual monotherapies.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab, with or without pomalidomide, for treating relapsed/refractory multiple myeloma (MMRR) from the second line of treatment onward. The Phase 3 MonumenTAL-3 trial demonstrated significant improvements in progression-free survival (81% at 24 months) and overall survival (89% at 24 months) compared to standard treatment, with manageable safety profiles consistent with individual drug profiles.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed/refractory multiple myeloma (RRMM) from the second line of therapy onward. The Phase 3 MonumenTAL-3 study demonstrated significant improvements in progression-free survival (81% at 24 months) and overall survival (89% at 24 months) compared to the control regimen, with safety profiles consistent with individual monotherapies.

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.

Johnson & Johnson has been assigned a Zacks Rank #4 (Sell) rating due to recent downward revisions in earnings estimates. While the company shows solid revenue growth projections of 7.4% for the current quarter and trades at fair valuation relative to peers, negative estimate revisions over the past month suggest potential near-term underperformance versus the broader market.

Johnson & Johnson and Amgen have outperformed the broader market in 2026 despite facing near-term challenges. JNJ's medtech division struggles with its Impella heart pump facing safety concerns and recalls, but its innovative medicines segment and new products like OTTAVA robotic surgery system offer long-term growth.

Amgen faces regulatory pressure on Tavneos and patent losses on denosumab, but strong pipeline candidates like MariTide and established growth drivers like Tezspire and Tepezza support its outlook. Both companies maintain excellent dividend track records, making them solid long-term income investments.

As AI dominates investment focus, healthcare and waste management sectors offer alternative diversification opportunities. Healthcare benefits from an aging population and rising medical needs, while waste management provides recurring revenue from essential services. Key companies like Abbott, Johnson & Johnson, Stryker, Waste Management, and Republic Services are positioned to capitalize on these structural trends.

AbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market.

Johnson & Johnson reported strong Q3 results with revenue beating expectations and raised full-year guidance, driven by excellent pharmaceutical segment performance including cancer drug Darzalex and autoimmune treatment Tremfya. However, the medtech division underperformed, particularly due to safety concerns with Impella heart pumps. Despite near-term headwinds, the article argues J&J remains a solid long-term buy given its robust pharmaceutical pipeline, upcoming medtech innovations like robotic surgery devices, and its status as a Dividend King with 64 consecutive years of dividend increases.

Johnson & Johnson raised its full-year sales and earnings guidance after beating Q3 estimates, but the stock fell 6% due to disappointing medical device sales. Despite near-term concerns about the MedTech division and a planned DePuy Synthes spinoff, the company's strong oncology business growth (16%+ in Q3) and reliable 64-year dividend streak make it an attractive long-term buy at current valuations.

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance.

However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.

Tech stocks faced headwinds this week as inflation concerns and rising bond yields pressured AI-related companies like Nvidia and Broadcom. CoreWeave's debt spike to $52 billion with 15% bond yields reignited AI debt bubble fears.

Despite strong earnings, TSMC, Johnson & Johnson, and Morgan Stanley all sold off, while JPMorgan rallied on solid lending metrics. Consumer spending signals remain mixed, with JPMorgan seeing strength but Domino's warning of economic headwinds.

Rocket Lab delayed Neutron's first flight to 2027 due to manufacturing issues. Valuation concerns persist across tech, with ASML, Atlassian, and Klarna highlighting the importance of entry price.

BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio.

Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027.

Johnson & Johnson raised its 2026 sales guidance to $101-$101.4 billion and adjusted EPS to $11.05-$11.15, driven by strong Innovative Medicine growth of 7.9%, particularly from TREMFYA (up 68.3%) and DARZALEX (up 15.4%). However, MedTech underperformed with only 2.5% growth due to competitive pressures and international headwinds. The company expects $1.36 per share in acquisition-related earnings in 2027 and targets double-digit growth by decade-end.

UnitedHealth and Johnson & Johnson both raised full-year guidance after Q3 earnings, but with contrasting performance. UnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management, while J&J saw earnings decline 7.5% YoY despite pharmaceutical growth offsetting weak MedTech performance. UnitedHealth is recommended as the better buy due to stronger earnings momentum, lower valuation (19X vs 23X forward earnings), and higher dividend yield (2.45% vs 2%).

Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%.

Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations.

Pre-market futures showed mixed signals as investors paused on AI stocks, with the Dow up 420 points while the Nasdaq fell 217 points. Oil prices dropped 1.5% amid Middle East tensions, and bond yields declined.

Small business optimism dipped for the second consecutive month in September. Major financial institutions reported Q3 earnings with mixed results: JPMorgan Chase missed estimates, Goldman Sachs significantly beat expectations, Wells Fargo delivered mixed results, and Johnson & Johnson beat on earnings but missed slightly on revenue.

Johnson & Johnson reported Q3 2026 adjusted earnings of $2.59 per share, beating estimates, but sales of $25.4 billion missed expectations. Innovative Medicine sales grew 7.7% driven by Tremfya and newer therapies, while Stelara faced significant biosimilar competition.

MedTech underperformed with a 2.5% increase missing estimates. J&J raised 2026 guidance but shares declined 2% in pre-market trading due to weaker-than-expected MedTech results.